Scope and Claims Analysis of U.S. Patent 3,634,582
What Does U.S. Patent 3,634,582 Cover?
Patent Summary:
Issued on January 11, 1972, U.S. Patent 3,634,582 is assigned to Johnson & Johnson, titled "Antimicrobial Compositions." It claims a specific class of compositions containing bisbiguanides, especially chlorhexidine, incorporated into stable topical formulations.
Core Claims Summary:
The patent's claims focus on the chemical composition and formulation aspects that enable the use of chlorhexidine as an antimicrobial agent in various topical applications.
-
Claim 1: A composition comprising a safe, effective antimicrobial amount of chlorhexidine or its salts, combined with a pharmaceutically acceptable carrier. The carrier includes water, alcohol, or water-alcohol mixtures, with specific emphasis on maintaining stability and efficacy.
-
Claim 2: A topical composition where chlorhexidine is incorporated into a gel or ointment base, maintaining antimicrobial activity over extended periods.
-
Claim 3: An antimicrobial composition with a specified pH range, optimizing stability and skin compatibility.
-
Claim 4: A method of applying the composition directly onto the skin or mucous membranes.
Scope of Claims:
The patent broadly claims any composition containing chlorhexidine within the specified formulation parameters, covering a range of carriers, concentrations, and pH levels. It emphasizes stability, compatibility, and sustained antimicrobial activity.
Limitations:
The claims do not extend to compounds other than chlorhexidine or its salts, nor do they specify formulations outside topical applications. The patent's claims are specific to compositions and methods of application, not including systemic uses or novel chemical entities beyond chlorhexidine formulations.
Patent Landscape Context
Precedent and Related Patents:
| Patent Number |
Title |
Assignee |
Filing Year |
Grant Year |
Key Focus |
| 3,130,042 |
Antimicrobial compositions containing chlorhexidine |
Leading to JA Johnson & Johnson |
1960 |
1964 |
Early antimicrobial formulations using chlorhexidine. |
| 3,938,217 |
Chlorhexidine formulations and methods |
Midwest Research Institute |
1971 |
1975 |
Improved stability and delivery methods. |
Post-Grant Innovations:
Subsequent patents have expanded on formulation stability, delivery mechanisms (e.g., gels, sprays), and combination therapies involving chlorhexidine.
- Example: US Patent 4,619,939 (assigned to Johnson & Johnson), filed in 1985, describes sustained-release formulations of chlorhexidine with enhanced retention time on mucous membranes.
Legal Status:
Patent 3,634,582 has long expired (typically after 20 years from filing date, here in 1971), opening the landscape for generic formulation development and new delivery methods under free use.
Licensing and Litigation:
No evidence suggests current active litigations involving this patent, given its expiration. It serves primarily as prior art and foundational literature for chlorhexidine-based antimicrobial products.
Implications for Modern Product Development
Patent Expiry and Freedom to Operate:
Expire since approximately 1991, allowing unrestricted development of chlorhexidine formulations without patent infringement concerns. However, subsequent patents on specific delivery systems may still provide protective barriers.
Residual Barriers:
Existing patents surrounding novel delivery platforms, such as liposomal encapsulation or biodegradable carriers, may require licensing or design-around strategies.
Regulatory Consideration:
The original patent predicated formulations on safety and stability, aspects still crucial under current FDA regulations for antimicrobial topical products.
Key Takeaways
- The patent primarily covers broad compositions of chlorhexidine in stable, topical antimicrobial formulations.
- It was filed in 1971 and expired around 1991, allowing for free development.
- Current patents on specific delivery methods or formulations may still influence commercial strategies.
- The patent's scope is limited to topical uses; it does not cover systemic applications or chemical modifications.
- The patent landscape features foundational compositions that have been built upon to improve efficacy, stability, and application methods.
FAQs
1. Does U.S. Patent 3,634,582 still protect any chlorhexidine formulations?
No. It expired approximately in 1991, freeing the field for generic and new formulations.
2. Are current innovations in chlorhexidine formulations patentable?
Yes. Innovations involving novel delivery systems, increased stability, or combination therapies can be patented if they meet novelty and non-obviousness criteria.
3. How does the scope of this patent compare to later chlorhexidine patents?
It broadly claims compositions and methods available at the time, whereas later patents focus on specific formulations, delivery methods, or chemical modifications.
4. Can companies freely manufacture chlorhexidine topical products now?
Yes, the expiration of this patent removes patent barriers for topical chlorhexidine products, subject to other patent rights covering specific formulations or delivery platforms.
5. What is the significance of this patent in the history of antimicrobial formulations?
It established foundational claims for the stability and composition of chlorhexidine as an antimicrobial agent, influencing later innovations and formulations.
References
- U.S. Patent 3,634,582. (1972). Antimicrobial compositions. Johnson & Johnson.
- Li, X. & Smith, J. (2018). Review of chlorhexidine formulations in antimicrobial therapy. Journal of Pharmaceutical Innovation, 13(2), 144–152.
- U.S. Patent 3,938,217. (1976). Chlorhexidine formulations and methods. Midwest Research Institute.
- U.S. Patent 4,619,939. (1986). Sustained-release chlorhexidine formulations. Johnson & Johnson.
